Spherical Nucleic Acids Deliver a New Package for Oliognucleotide Therapeutics
SNAs Are a Hopeful First Step in Boosting the Utility of Oligonucleotides to Treat a Variety of Human Diseases
Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
For full access to this article login to GEN Select now.
CMOs Find Opportunities in Biologics
Biomanufacturing Companies Provide Services From Preclinicals through All Clinical Phases
- The first attempts to use monoclonals (Mabs) as antitumor agents in the 1980s did not live up to expectations. The recent success of improved therapeutic Mabs, such as Rituxan for cancer and Remicade for arthritis, are proving clinically effective and financially attractive. This resurgent interest in Mabs creates opportunities ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.